Akums Launches High-Strength Paracetamol Oral Suspension 500mg/5ml for Enhanced Adult and Elderly Care in India

New Delhi, July 23, 2025 - Akums Drugs & Pharmaceuticals Ltd. India's largest pharmaceutical manufacturing organisation, has announced the launch of Paracetamol Oral Suspension 500mg/5ml in the Indian market. This high-strength, easy-to-administer formulation is designed to improve pain and fever management in adult and geriatric patients.
This novel oral suspension marks a significant addition to the analgesic and antipyretic category by offering therapeutic adult dosing in a minimal volume. It addresses the growing demand in India for liquid formulations suitable for patients who have difficulty swallowing tablets. With this launch, Akums bridges the long-standing gap between paediatric syrups and conventional tablet formats, providing a patient-friendly alternative that promotes better treatment adherence.
Paracetamol 500mg/5ml is among the most concentrated liquid paracetamol formulations available in the Indian market. By delivering an effective adult dose in just 5ml, it significantly reduces dosing frequency and volume-particularly beneficial in outpatient, hospital, and home care settings across India. It enables rapid symptom relief, especially in cases where IV access is unavailable or oral tablets are are ineffective or cause discomfort.
Designed for real-world convenience, this oral suspension supports better compliance, especially in elderly patients, post-surgical recovery cases, and those with dysphagia or swallowing difficulties. Compared to traditional 250mg/5ml suspensions available in the market, which require 10-20ml per dose, the new formulation minimises confusion and enhances caregiver ease with a straightforward "5ml = 500mg" format-especially helpful in homecare and community health scenarios commonly seen in the Indian market.
Mr. Sandeep Jain, Joint Managing Director of Akums Drugs & Pharmaceuticals Ltd., said ''At Akums, we always strive to develop solutions that make a real difference in people's lives. This new high-strength paracetamol suspension is a result of listening to what patients and caregivers truly need-something effective, easy to take, and less of a burden during times of illness. Whether it's for an elderly person struggling to swallow tablets or someone managing care at home, we believe this product will make treatment simpler and more comfortable. It's another step in our journey to create accessible and thoughtful healthcare solutions for everyone."
The product also reflects broader healthcare trends observed in India post-COVID-such as the rise in home-based care, and growing demand for convenient, easy-to-administer treatment formats. With increased awareness around medication compliance and simplified regimens,, Akums' latest offering is well-aligned with the shift toward more accessible and user-friendly healthcare solutions across the country.
This launch further strengthens Akums' leadership in the pain and fever management category within the Indian market and reflects the company's strategic focus on differentiated dosage forms and real-world applicability. While it is being rolled out initially for Indian patients, the formulation also holds potential for expansion into international markets with similar healthcare needs and patient preferences.

Akums Drugs and Pharmaceuticals Ltd, Phase -1, Ind. Area, Plot No. 131 to 133, adjoining CBSE Office, Block C, Mangolpuri, Delhi, 110083

Akums Drugs & Pharmaceuticals Ltd. is India's leading contract development and manufacturing organization (CDMO), recognized for its unmatched capabilities in delivering high-quality pharmaceutical and nutraceutical products. With a robust infrastructure comprising 12 advanced manufacturing facilities and a portfolio of over 4,025 commercialized formulations, Akums serves both domestic and global markets with efficiency, innovation, and reliability.

Founded with a vision to set new benchmarks in pharmaceutical manufacturing, Akums offers end-to-end solutions-from product development and regulatory support to large-scale manufacturing-across multiple dosage forms including tablets, capsules, injectables, softgels, topical applications, and effervescent formulations. The company's dedicated R&D division continuously drives innovation, enabling the development of cutting-edge and differentiated products tailored to evolving market needs.

Employing over 16,000 skilled professionals, Akums adheres to the highest global standards of quality, safety, and compliance. It proudly serves more than 600 clients worldwide, including some of the most respected names in healthcare.

With an unwavering commitment to excellence and a deep sense of responsibility towards patients and partners, Akums is not just manufacturing medicines-it's shaping a healthier future for all.

This release was published on openPR.